Future studies should focus on overcoming the limitations of the current research and explore the following promising directions: First, large-scale multi-center studies should validate the clinical utility of identified biomarkers (such as GPX8, COMP, and ASPN) in different IPF populations to determine their potential as diagnostic tools. The gene discussed is COMP; the disease is idiopathic pulmonary fibrosis.